Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2022 - 2023)

Capricor Therapeutics has reported Non-Current Deffered Revenue over the past 4 years, most recently at $953470.0 for Q3 2023.

  • Quarterly results put Non-Current Deffered Revenue at $953470.0 for Q3 2023, down 90.27% from a year ago — trailing twelve months through Sep 2023 was $953470.0 (down 90.27% YoY), and the annual figure for FY2022 was $9.5 million, changed.
  • Non-Current Deffered Revenue for Q3 2023 was $953470.0 at Capricor Therapeutics, down from $3.2 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for CAPR hit a ceiling of $20.3 million in Q1 2022 and a floor of $953470.0 in Q3 2023.